Curis (NASDAQ:CRIS) Stock Rating Lowered by Zacks Research

Curis (NASDAQ:CRIS) was downgraded by Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday,Zacks.com reports.

A number of other analysts have also weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $43.00 target price (up from $17.00) on shares of Curis in a report on Friday, July 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a report on Friday, July 17th. Finally, Wall Street Zen lowered shares of Curis to a “strong sell” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average target price of $43.00.

Curis Stock Down 27.7%

Shares of CRIS opened at $1.67 on Tuesday. Curis has a twelve month low of $1.63 and a twelve month high of $39.00. The stock has a market cap of $3.49 million, a PE ratio of -0.07 and a beta of 3.13. The business’s 50-day moving average price is $6.15 and its 200-day moving average price is $11.93.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($25.00) EPS for the quarter, missing analysts’ consensus estimates of ($6.53) by ($18.47). Analysts expect that Curis will post -33.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Curis

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC raised its position in shares of Curis by 8.7% during the 3rd quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares in the last quarter. Maverick Capital Ltd. raised its position in Curis by 7.8% during the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after purchasing an additional 49,554 shares in the last quarter. Renaissance Technologies LLC raised its position in Curis by 52.2% during the first quarter. Renaissance Technologies LLC now owns 366,740 shares of the biotechnology company’s stock valued at $201,000 after purchasing an additional 125,823 shares in the last quarter. Flputnam Investment Management Co. bought a new stake in Curis during the second quarter worth about $128,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in Curis by 2,883,237.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after purchasing an additional 230,659 shares during the last quarter. Institutional investors own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.